March 2020 - Evolution Biotechnologies
0
archive,date,ajax_fade,page_not_loaded,,qode-title-hidden,qode-theme-ver-16.4,qode-theme-bridge,wpb-js-composer js-comp-ver-5.4.7,vc_responsive

Bedford, UK, March 18th 2020 Evolution Biotechnologies (www.evolutionbiotech.com), the UK-based company pioneering the use of biological control to benefit human health, today reports the appointment of Panda New Capital (PNC) and its partners as global financial advisors to the company. Evolution has been working with Panda New Capital (PNC) since late 2019 and has agreed to expand the roles of PNC and its partner companies from Asian markets to a global role. Dr. David Harper, Evolution’s CEO, said “we see expansion into Asia as a key priority for the company and we have found working with Panda New Capital to be highly productive....